Previous
Previous

Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis

Next
Next

The potential impact of digial biomarkers in multiple slerosis in the Netherlands: an early HTA technology assessment of MS Sherpa